US 12,012,422 B2
Copper complexes for treatment of neurodegenerative disorders
Matvey Lukashev, Upton, MA (US); Alexei Pushechnikov, San Diego, CA (US); Peter Demin, Moscow (RU); and Kyle Denton, Medford, MA (US)
Assigned to ALS THERAPY DEVELOPMENT INSTITUTE, Cambridge, MA (US)
Filed by ALS Therapy Development Institute, Cambridge, MA (US)
Filed on Aug. 26, 2021, as Appl. No. 17/458,021.
Claims priority of provisional application 63/070,792, filed on Aug. 26, 2020.
Prior Publication US 2023/0054997 A1, Feb. 23, 2023
Int. Cl. C07F 1/08 (2006.01); A61P 25/28 (2006.01); C07F 9/54 (2006.01)
CPC C07F 1/08 (2013.01) [A61P 25/28 (2018.01); C07F 9/5442 (2013.01)] 14 Claims
 
1. A compound of Formula (V):

OG Complex Work Unit Chemistry
or pharmaceutically acceptable salts thereof, wherein:
R1 is C1-C6 alkyl optionally substituted with 5- to 10-membered heteroaryl, NH2, NH(C1-C6 alkyl), or N(C1-C6 alkyl)2;
R2 is C1-C6 alkyl optionally substituted with 5- to 10-membered heteroaryl, NH2, NH(C1-C6 alkyl), or N(C1-C6 alkyl)2;
R3 is furyl optionally substituted one time with C1-C3 alkyl-N(C1-C4 alkyl)2 or C1-C3 alkyl-(5- to 6-membered heterocycle), wherein the 5- to 6-membered heterocycle is optionally further substituted one to four times with C1-C3 alkyl; and
R4 is hydrogen or C1-3 alkyl.